PARP Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2020

Table of Content

1. Report Introduction

2. PARP Inhibitors
2.1. PARP Inhibitors Overview
2.2. PARP Inhibitors Types
2.3. PARP Inhibitors Structure
2.4. PARP Inhibitors Mechanism of Action
2.5. PARP Inhibitors Application

3. Competitive Landscape
3.1. Marketed Product Profiles
3.1.1. Zejula: Tesaro
3.1.1.1. Product Description
3.1.1.2. Research and Development
3.1.1.2.1. Clinical Studies
3.1.1.3. Other Pipeline Activities
3.1.1.4. Product Development Activities
3.1.1.5. Idhifa Sales

4. PARP Inhibitors - DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. PARP Inhibitors Companies Collaborations, Licensing, Acquisition – Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. PARP Inhibitors Collaboration Deals
4.1.2.1. Company–Company Collaborations (Licensing/Partnering) Analysis
4.1.2.2. Company–University Collaborations (Licensing/Partnering) Analysis
4.1.2.3. PARP Inhibitors Acquisition Analysis

5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Stage of Development
5.1.2. Assessment by Product Type (Mono/Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target

6. Pipeline Therapeutics
6.1. Comparative Analysis

7. Late-Stage Products (Phase-III)

8. Mid-Stage Products (Phase-II)

9. Early-Stage Products (Phase-I)

10. Preclinical and Discovery Stage Products

11. PARP Inhibitors Emerging Drug Profiles
11.1. CVA 21: Merck
11.1.1. Product Description
11.1.2. Research and Development
11.1.2.1. Clinical Studies
11.1.3. Product Development Activities
11.1.4. Tabulated Product Summary
11.1.4.1. General Description Table
Many more drugs with detailed profiles provided in the report ?

12. PARP Inhibitors Key Companies

13. PARP Inhibitors Key Products

14. Inactive Products
14.1. Dormant Products
14.1.1. Reason for Dormancy
14.2. Discontinued Products
14.2.1. Reason for Discontinuation

15. PARP Inhibitors - Unmet Needs

16. PARP Inhibitors – Market Drivers and Barriers

17. PARP Inhibitors - Future Perspectives and Conclusion

18. PARP Inhibitors Analyst Views

19. Appendix

20. Report Methodology
20.1. Secondary Research
20.2. Expert Panel Validation

List of Figures

Figure 1 PARP Inhibitors Structure
Figure 2 PARP Inhibitors Mechanism
Figure 3 PARP Inhibitors Types
Figure 4 PARP Inhibitors Clinical Significance
Figure 5 PARP Inhibitors companies collaborations, Licensing, Acquisition – Deal Value Trends
Figure 6 Company–Company Collaborations (Licensing/Partnering) Analysis
Figure 7 PARP Inhibitors Acquisition Analysis
Figure 8 Assessment by Phase of Development
Figure 9 Assessment by Product Type (Mono/Combination)
Figure 10 Assessment by Stage and Product Type
Figure 11 Assessment by Route of Administration
Figure 12 Assessment by Stage and Route of Administration
Figure 13 Assessment by Molecule Type
Figure 14 Assessment by Stage and Molecule Type
Figure 15 Assessment by MOA
Figure 16 Assessment by Stage and MOA
Figure 17 Late-Stage Products (Phase-III)
Figure 18 Mid-Stage Products (Phase-II)
Figure 19 Early-Stage Products (Phase-I)
Figure 20 Preclinical and Discovery Stage Products
Figure 21 Inactive Products
Figure 22 Dormant Products
Figure 23 Discontinued Products
Figure 24 Unmet Needs
Figure 25 Market Drivers and Barriers

List of Tables

Table 1 Assessment Summary
Table 2 Company-Company Collaborations (Licensing/Partnering) Analysis
Table 3 PARP Inhibitors Acquisition Analysis
Table 4 Assessment by Phase of Development
Table 5 Assessment by Product Type (Mono/Combination)
Table 6 Assessment by Stage and Product Type
Table 7 Assessment by Route of Administration
Table 8 Assessment by Stage and Route of Administration
Table 9 Assessment by Molecule Type
Table 10 Assessment by Stage and Molecule Type
Table 11 Assessment by MOA
Table 12 Assessment by Stage and MOA
Table 13 Assessment by Target
Table 14 Assessment by Stage and Target
Table 15 Late-Stage Products (Phase-III)
Table 16 Mid-Stage Products (Phase-II)
Table 17 Early-Stage Products (Phase-I)
Table 18 Preclinical and Discovery Stage Products
Table 19 Inactive Products
Table 20 Dormant Products
Table 21 Discontinued Products